Trial Profile

A phase I trial of intra-arterial delivery of SL 052 photodynamic therapy in patients with localised prostate cancer.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SL 052 (Primary)
Indications Prostate cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Quest PharmaTech

Most Recent Events

29 Nov 2011 Status changed from planning to recruiting, according to a Quest PharmaTech media release.
11 May 2010 Planned number of patients changed from 12 to 18 according to Quest PharmaTech media release.
11 May 2010 According to a company media release, Quest PharmaTech has begun dosing of the first patient in this Phase I clinical trial of SL052 Photodynamic Therapy in prostate cancer patients.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com